Vamil Divan

Stock Analyst at Guggenheim

(2.65)
# 763
Out of 5,441 analysts
287
Total ratings
Success rate
Average return
49 Stocks
Name Action PT Current % Upside Ratings Updated
ABBV AbbVie
Maintains: Strong Buy
216 227
198.62 14.29% 24 Aug 1, 2025
JNJ Johnson & Johnson
Maintains: Neutral
164 167
173.87 -3.95% 16 Jul 17, 2025
PROK ProKidney
Maintains: Strong Buy
6 7
2.25 211.11% 2 Jul 14, 2025
JBIO Jade Biosciences
Upgrades: Buy
14
n/a n/a 1 Jun 16, 2025
SVRA Savara
Maintains: Buy
9 8
2.71 195.2% 1 May 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Neutral
288
285.1 1.02% 1 May 20, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
86 86
84.89 1.31% 11 May 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
15 14
8.5 64.71% 1 May 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
60
4.01 1396.26% 1 Apr 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
115 115
80.06 43.64% 9 Apr 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
47 47
17.29 171.83% 8 Apr 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
31
23.54 31.69% 1 Mar 25, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
10 10
2.85 250.88% 3 Mar 20, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
n/a
n/a n/a 17 Mar 18, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
59 61
20.18 202.28% 5 Feb 27, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
101 101
112.87 -10.52% 6 Feb 25, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
n/a
n/a n/a 5 Jan 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
7 4
3.65 -15.07% 6 Dec 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Jun 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
55
64.97 -15.35% 1 Apr 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
245 330
329.83 0.05% 7 Jan 26, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
19 20
8.68 130.41% 9 Sep 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
21 18
40 -55% 2 Aug 18, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
26
0.56 4542.86% 2 Jun 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
35 40
40.39 -0.97% 3 Jun 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
8 9
0.88 922.73% 2 Apr 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
n/a
n/a n/a 1 Mar 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
13 2
1.1 81.82% 5 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
27 19
24.83 -23.48% 7 Aug 10, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
95 98
123.99 -20.96% 8 Aug 8, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
36 34
26.55 28.06% 7 Jul 28, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
20 10
1.32 657.58% 3 May 25, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
51 49
103.95 -52.86% 3 May 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
315 356
635.48 -43.98% 15 May 2, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
8 6
7.21 -16.78% 1 Mar 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
144 154
13.43 1046.69% 9 Mar 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
15
5.76 160.42% 5 May 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 6 Dec 13, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
7 4
n/a n/a 6 Nov 8, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
11 19
n/a n/a 8 Sep 17, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Neutral
35
n/a n/a 13 Aug 5, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Neutral
n/a
n/a n/a 13 Jul 10, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
36 30
n/a n/a 4 May 21, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
161 155
n/a n/a 10 Mar 7, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
15
4.37 243.25% 4 Aug 15, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
58 61
45.94 32.78% 5 Jul 27, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
103
1.85 5467.57% 3 Jan 17, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
45 55
n/a n/a 1 Sep 19, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
66 120
n/a n/a 4 Dec 20, 2016